from NPR
There is growing interest in reducing the evidence required to approve new drugs and to more rapidly deliver new therapies to patients. The sentiment behind speeding approval is a good one—no one wants to delay the availability of drugs that are beneficial and safe—but can lead to shortcuts in evidence generation that can also come with risk.
Disclaimer: The viewpoint expressed in this article is the opinion of the author and is not necessarily the viewpoint of the owners or employees at Healthcare Staffing Innovations, LLC.
0 likes